Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 802 results for "sandoz inc"

Amgen, Inc. Succeeds In Blocking Neupogen Biosimilar US Launch...

Amgen, Inc. ( NASDAQ:AMGN ) has succeeded yet again in its aggressive efforts aimed at preventing Sandoz, the generics drug unit of Novartis AG (ADR) ( NYSE:NVS ), from launching a biosimilar version of its blockbuster cancer drug Neupogen in the ... Bidness Etc, 2 weeks ago

1 images for "sandoz inc"

Maryland Gazette, 1 month ago

Momenta announces FDA approval for Sandoz's multiple sclerosis drug

Momenta Pharmaceuticals, Inc., a biotechnology company, has announced that the FDA has granted marketing approval for Sandoz's abbreviated new drug application, or ANDA, for Glatopa 20mg/mL, a once daily, generic equivalent of COPAXONE 20mg, ...
 Individual.com1 month ago FDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz and Momenta -- Update  4 Traders1 month ago

Amgen Prevails on Temporarily Excluding Zarxio® From Market

After an unsuccessful attempt to obtain a preliminary injunction against Sandoz Inc.'s (Sandoz) Zarxio® [1] in the District Court for the Northern District of California, [2] Amgen Inc. (Amgen) has prevailed before the Federal Circuit in excluding ...
 JD Supra2 weeks ago US judge rejects Amgen injunction bid against Novartis Sandoz unit  Economic Times2 months ago

Court halts sale of first FDA-approved biosimilar

The sale of Sandoz's biosimilar version of Amgen Inc,'s drug Neupogen is on hold. Source: Healthcare Packaging: News, trends and analysis of pharmaceuticals, biologics, medical devices, and nutraceuticals
 Converter News2 weeks ago Global Biosimilar Market Outlook 2020  Town Hall4 weeks ago Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth  TickerTech.com4 days ago Zarxio®, First BPCIA Approved Biosimilar, Added to Purple Book  JD Supra1 month ago

Revisiting claim construction after the Supreme Court's decision in Teva v. Sandoz

Unfortunately, the Supreme Court's Teva decision has left us some open questions In Teva Pharm. U.S.A. Inc. v. Sandoz, Inc., the Supreme Court ruled that the Court of Appeals for the Federal Circuit should review a district court's factual ...
 Inside Counsel2 weeks ago Spectrum Pharms., Inc. v. Sandoz Inc.  JD Supra3 weeks ago Teva Pharms USA, Inc. v. Sandoz, Inc.  JD Supra1 month ago IP Newsflash - May 2015 #2  JD Supra2 weeks ago

Law360 Covers Federal Circuit Win for Sandoz in Asthma Drug Patent Dispute

Steptoe's Federal Circuit win for Sandoz Inc. in a patent dispute over a children's asthma drug was covered by Law360 in an article titled "Fed. Circ. Affirms Invalidity of AstraZeneca Inhaler Patent." The article discusses a May 7 decision from the ...
 Noodls2 weeks ago Federal Circuit Keeps Sandoz Biosimilar Off The Market For Now  National Law Review2 weeks ago

Petitioners Must Present Sufficient Evidence to Establish Inherency

Last Friday the Patent Trial and Appeal Board (PTAB) denied four Sandoz Inc. petitions for instituting inter partes review (IPR) of U.S. 8,455,524 (IPR2015-00005), U.S. 7,612,102 (IPR2015-00006), U.S. 7,659,290 (IPR2015-00007), and U.S. 7,659,291 B2 ...
 National Law Review3 weeks ago

MNTA Prices Offering At $19/Share

Momenta Pharmaceuticals Inc. (MNTA: Quote) has offered to sell 7.25 million shares of its common stock to the public at a price of $19.00 each. The underwriters have an option to purchase up to an additional 1.08 million shares of the company's ...
 RTTNews.com1 week ago Anacor Pharmaceuticals Reports First Quarter 2015 Financial Results  Pharmacy Choice1 week ago InSite Vision, Inc. (INSV: OTCQB) | InSite Vision Reports First Quarter 2015 Financial Results  OTC Markets2 weeks ago MOMENTA PHARMACEUTICALS INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  Pharmacy Choice3 weeks ago

Spectrum Pharmaceuticals: Our Thoughts On Armistice Capital's 13D

May. 18, 2015 9:38 AM ET | About: Spectrum Pharmaceuticals, Inc. (SPPI) by: Summary We continue to find meaningful downside to SPPI from its current stock price. SPPI's assets do not fit our view of the criteria of recent M&A deals in the ...
 Seeking Alpha1 week ago

Biosimilar Market Ebbs And Flows Push Epirus Down To Attractive Valuation

ceuticals, Inc (EPRS) by: Jason Napodano, CFA Subscribers to SA PRO had an early look at this article. Learn more about PRO » Summary In March 2015, the U.S. FDA approved the first biosimilar product in the U.S. in Novartis' Zarxio, a ...
 Seeking Alpha1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less